العلاج الدوائي التوليفي لمرض باركنسون

References

DOI: 10.1186/s42466-024-00325-4

• Pharmacological combination therapy should be considered following initial monotherapy when the efficacy of the initial monotherapy at an intermediate maintenance dose for dopa-sensitive target symptoms is inadequate or when the monotherapy's required dosage for symptom control cannot be achieved due to therapy-limiting side effects.
• Various combinations of Levodopa-preparations with dopamine-agonists and/or MAO-B inhibitors may be considered for combination therapy of PD without fluctuations.